Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis
Open accessAbstract
Background & aims Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD.Methods We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical response, as determined by the treating clinician or measurements of fecal calprotectin. Remission was defined more stringently as endoscopic mucosal healing. We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy.Results Anti-TNF treatment produced a response of IBD in 48% of patients and remission of IBD in 23%. There was no difference in PSC symptom frequency before or after drug exposure. The most common reasons for anti-TNF discontinuation were primary nonresponse of IBD (17%) and side effects (18%). At 3 months, infliximab-treated patients had a median reduction in serum level of ALP of 4% (interquartile range, reduction of 25% to increase of 19%) compared with a median 15% reduction in ALP in adalimumab-treated patients (interquartile range, reduction of 29% to reduction of 4%; P = .035). Factors associated with lower ALP were normal ALP at baseline (P < .01), treatment with adalimumab (P = .090), and treatment in Europe (P = .083).Conclusions In a retrospective analysis of 141 patients with PSC and IBD, anti-TNF agents were moderately effective and were not associated with exacerbation of PSC symptoms or specific side effects. Prospective studies are needed to investigate the association between use of adalimumab and reduced serum levels of ALP further.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Anti-TNF treatment is moderately effective for gut inflammation in PSC-IBD and no concerning safety signals were found.
“Treatment was shown to be moderately effective for gut inflammation and no concerning safety signals were found.”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [182]
Side effects of anti-TNF treatment in PSC-IBD are similar to those in IBD alone, with no exacerbation of PSC symptoms or specific liver-related side effects.
“The side effects of anti-TNF treatment in PSC-IBD are reported to be similar to those in IBD alone, and no exacerbation of PSC symptoms or specific liver-related side effects have been noted.182”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [182]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Primary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868 · see citing works
Self-citationHigh-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720 · see citing works
Primary Sclerosing Cholangitis, Inflammatory Bowel Disease, and Colon Cancer
Broomé, U., & Bergquist, A. M. (2006) · Seminars in Liver Disease · doi:10.1055/s-2006-933561 · Cited by 244 · see citing works
Self-citationHedin, C. R. H., Vavricka, S., Stagg, A. J., Schoepfer, A. M., Raine, T., Puig, L., Pleyer, U., Navarini, A. A., Jong, A. E. V. D. M., Maul, J., et al. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy191 · Cited by 232 · see citing works
Self-citationPredictors of early response to infliximab in patients with ulcerative colitis
Ferrante, M., Vermeire, S., Katsanos, K. H., Noman, M., Assche, G. V., Schnitzler, F., Arijs, I., Hertogh, G. D., Hoffman, I. E. A., Geboes, K. J., et al. (2006) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20054 · Cited by 192 · see citing works
Self-citationPonsioen, C. Y., Chapman, R. W., Chazouillères, O., Hirschfield, G. M., Karlsen, T. H., Lohse, A. W., Pinzani, M., Schrumpf, E., Trauner, M. A., & Gores, G. J. (2015) · Hepatology · doi:10.1002/hep.28256 · Cited by 177 · see citing works
Self-citationPalmela, C., Peerani, F., Castañeda, D., Torres, J., & Itzkowitz, S. H. (2017) · Gut and Liver · doi:10.5009/gnl16510 · Cited by 176 · see citing works
Sprakes, M. B., Ford, A. C., Warren, L. R., Greer, D., & Hamlin, P. J. (2011) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2011.07.011 · Cited by 152 · see citing works
Marelli, L., Xirouchakis, E., Kalambokis, G. N., Cholongitas, Ε., Hamilton, M., & Burroughs, A. K. (2011) · Gut · doi:10.1136/gut.2010.235408 · Cited by 113 · see citing works
Lynch, K. D., Chapman, R. W., Keshav, S., Montano-Loza, A. J., Mason, A. L., Kremer, A. E., Vetter, M., de Krijger, M., Ponsioen, C. Y., Trivedi, P., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.013 · Cited by 105 · see citing works
Self-citationLindström, L., Jørgensen, K. K., Boberg, K. M., Castedal, M., Rasmussen, A., Rostved, A. A., Isoniemi, H., Bottai, M., & Bergquist, A. M. (2018) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1421705 · Cited by 104 · see citing works
Self-citationBile acids for primary sclerosing cholangitis
Poropat, G., Giljača, V., Štimac, D., & Gluud, C. N. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003626.pub2 · Cited by 98 · see citing works
Nordenvall, C., Olén, O., Nilsson, P. J., von Seth, E., Ekbom, A., Bottai, M., Myrelid, P., & Bergquist, A. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14393 · Cited by 78 · see citing works
Self-citationThorlund, K., Druyts, E., Mills, E. J., Fedorak, R. N., & Marshall, J. K. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.01.010 · Cited by 77 · see citing works
Tse, C. S., Loftus, E. V., Raffals, L. E., Gossard, A. A., & Lightner, A. L. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14829 · Cited by 76 · see citing works
Baert, F., Casteele, N. V., Tops, S., Noman, M., Assche, G. V., Rutgeerts, P., Gils, A., Vermeire, S., & Ferrante, M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12968 · Cited by 69 · see citing works
Self-citationSpanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU)., Iborra, M., Gisbert, J. P., Boscá-Watts, M. M., López‐García, A., García-Sánchez, V., López–Sanromán, A., Hinojosa, E., Márquez, L., García‐López, S., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1274-1 · Cited by 64 · see citing works
Caron, B., Peyrin-Biroulet, L., Pariente, B., Bouhnik, Y., Seksik, P., Bouguen, G., Caillo, L., Laharie, D., Carbonnel, F., Altwegg, R., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz088 · Cited by 60 · see citing works
Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU)., Iborra, M., Gisbert, J. P., Boscá-Watts, M. M., López‐García, A., García-Sánchez, V., López–Sanromán, A., Hinojosa, E., Márquez, L., García‐López, S., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1293-y · Cited by 52 · see citing works
Church, P. C., Hyams, J. S., Ruemmele, F. M., de Ridder, L., Turner, D., & Griffiths, A. M. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/3190548 · Cited by 25 · see citing works
Ong, J., Bath, M., Swift, C., & Al‐Naeeb, Y. (2018) · Gastroenterology and hepatology from bed to bench. · doi:10.17863/cam.52127 · Cited by 12 · see citing works
Ringe, K. I., Grigoriadis, A., Halibasic, E., Wacker, F. K., Manns, M. P., Schramm, C., Lenzen, H., & on behalf of the MRI working group of the IPSCSG (2018) · Hepatology · doi:10.1002/hep.30276 · Cited by 9 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Bowlus, C. L., Arrivé, L., Bergquist, A. M., Deneau, M. R., Forman, L., Ilyas, S. I., Lunsford, K. E., Martínez, M., Sapisochín, G., Shroff, R. T., et al. (2022) · Hepatology · doi:10.1002/hep.32771 · Cited by 448 · see citing works
Self-citationEASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419 · see citing works
Self-citationTNF in the liver: targeting a central player in inflammation
Tiegs, G., & Horst, A. K. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00910-2 · Cited by 231 · see citing works
The microbiota and the gut–liver axis in primary sclerosing cholangitis
Hov, J. R., & Karlsen, T. H. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00690-y · Cited by 121 · see citing works
Inflammatory bowel disease and primary sclerosing cholangitis: One disease or two?
van Munster, K. N., Bergquist, A. M., & Ponsioen, C. Y. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.09.031 · Cited by 115 · see citing works
Self-citationVesterhus, M. N., & Karlsen, T. H. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01681-z · Cited by 80 · see citing works
Self-citationPrimary sclerosing cholangitis
Manns, M. P., Bergquist, A. M., Karlsen, T. H., Levy, C., Muir, A. J., Ponsioen, C. Y., Trauner, M., Wong, G. L., & Younossi, Z. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00600-x · Cited by 71 · see citing works
“Experiences with a long list of agents with immunosuppressive potency and biologicals, such as anti-TNF strategies and, more recently, the α4β7 integrin blocker vedolizumab, have so far been rather disappointing for PSC 1,269–273 .”
Self-citationVedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease
Hanžel, J., Ma, C., Casteele, N. V., Khanna, R., Jairath, V., & Feagan, B. G. (2021) · Drugs · doi:10.1007/s40265-020-01460-3 · Cited by 41 · see citing works
Therapeutic modulation of the liver immune microenvironment
Tilg, H., Adolph, T. E., & Tacke, F. (2023) · Hepatology · doi:10.1097/hep.0000000000000386 · Cited by 31 · see citing works
“[157] In a French nationwide cohort, 1929 patients with PSC/IBD exposed to thiopurines and/or anti-TNF agents did not show an excess risk of biliary tract cancer or need for liver transplantation.”
BackgroundShah, A., Jones, M. P., Callaghan, G., Fairlie, T., Ma, X., Culver, E. L., Stuart, K. A., Cruz, P. P. D., O’Beirne, J. P., Tabibian, J. H., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000347 · Cited by 30 · see citing works
“Only one study [21] included post-liver transplant recipients with PSC-IBD.”
BackgroundResultInfluentialImmunobiology of primary sclerosing cholangitis
Cornillet, M., Geanon, D., Bergquist, A., & Björkström, N. K. (2025) · Hepatology · doi:10.1097/hep.0000000000001080 · Cited by 20 · see citing works
Self-citationCurrent Therapeutics in Primary Sclerosing Cholangitis
Tan, N., Lubel, J. S., Kemp, W. W., Roberts, S. K., & Majeed, A. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00068s · Cited by 17 · see citing works
Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
Kim, Y. S., Hurley, E., Park, Y., & Ko, S. (2023) · Intestinal Research · doi:10.5217/ir.2023.00039 · Cited by 17 · see citing works
“In terms of safety, anti-TNF agents did not exacerbate PSC symptoms or side effects such as cholangitis.(40) Another retrospective study also found that adalimumab (n = 19) treatment showed a significant decrease in serum ALP after 6 to 8 months (P = 0.”
BackgroundLiu, X., Wang, H., Liu, X., Bridle, K. R., Crawford, D. H., & Liang, X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108163 · Cited by 16 · see citing works
Emerging drugs for the treatment of primary sclerosing cholangitis
Abbas, N., Quraishi, M. N., & Trivedi, P. J. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.003 · Cited by 16 · see citing works
Primary sclerosing cholangitis
von Seth, E., Karlsen, T. H., Tanaka, A., Ponsioen, C. Y., & Bergquist, A. M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02582-6 · Cited by 17 · see citing works
Self-citationvan Rheenen, P. F., Kolho, K., Russell, R. K., Aloi, M., Deganello, A., Hussey, S., Junge, N., de Laffolie, J., Deneau, M. R., Fitzpatrick, E., et al. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12378 · Cited by 14 · see citing works
Recent advances in the treatment of primary sclerosing cholangitis
Bjornsson, E. S., & Kalaitzakis, E. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1860751 · Cited by 16 · see citing works
“Among patients on TNFinhibitors, adalimumab but not infliximab was associated with a significant reduction in ALP [119,122].”
BackgroundMedical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
Karlsen, T. H., Jørgensen, K. K., & Bergquist, A. M. (2024) · Hepatology · doi:10.1097/hep.0000000000001172 · Cited by 14 · see citing works
“[67] A positive IBD response at 3 months was however predictive of a lower ALP level at 12 months, raising the possibility that this effect of adalimumab on ALP levels was merely due to a reduction of intestinal inflammation.”
Self-citationClinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead
Chen, Y., Chen, R., Li, H., & Shuai, Z. (2025) · Immunologic Research · doi:10.1007/s12026-025-09622-9 · Cited by 14 · see citing works
Båve, A. L., Olén, O., Söderling, J. K., SWIBREG study Group, Ludvigsson, J. F., Bergquist, A. M., & Nordenvall, C. A. M. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12388 · Cited by 13 · see citing works
“Ethical approval was obtained from the ethical vetting board of the Stockholm region (2007/785‐31/5; 2011/1509‐32; 2012/601‐ 32, 2015/0004–31, 2015/615‐32, 2015/1030‐ 32, 2015/2237‐32, Key summary Summarize the established knowledge on this subject � There is a close clinical link between UC and PSC. � The gut‐liver‐a…”
BackgroundInfluentialSelf-citationCellular interactions in self-directed immune-mediated liver diseases
Bozward, A. G., Davies, S. P., Morris, S. M., Kayani, K., & Oo, Y. H. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.002 · Cited by 12 · see citing works
The role of TNF in metabolic disorders and liver diseases
Xu, C., Ezzi, S. H. A., Zou, X., Dong, Y., Alhaskawi, A., Zhou, H., Kota, V. G., Abdulla, M. H. A. H., Abdalbary, S. A., & Lu, H. J. (2025) · Cytokine · doi:10.1016/j.cyto.2025.156933 · Cited by 11 · see citing works
PSC and colitis: A complex relationship
Horst, L. J., Kempski, J., Walmsley, M., Huber, S., & Schramm, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001236 · Cited by 10 · see citing works
Self-citationPinnuck, B. C., & Lynch, K. D. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2407022 · Cited by 7 · see citing works
“Also important to note is the retrospective report of twelve patients with PSC-IBD who have undergone LT and received anti-TNF therapy (unclear breakdown of infliximab and adalimumab) at a median of 2.3 years following LT [31].”
InfluentialSelf-citationTreatment sequencing in inflammatory bowel disease: Towards clinical precision medicine
Sequier, L., Caron, B., Honap, S., Caillo, L., Altwegg, R., Netter, P., Fuméry, M., Buisson, A., & Peyrin‐Biroulet, L. (2025) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2025.101994 · Cited by 7 · see citing works
Sayed, A., Assis, D. N., Silveira, M. G., Deng, Y., Ciarleglio, M. M., Gaidos, J. K. J., Proctor, D. D., & Al‐Bawardy, B. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002510 · Cited by 7 · see citing works
An overview of recent treatment options for primary sclerosing cholangitis
Mousavere, I. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0834 · Cited by 6 · see citing works
“A retrospective study involving 141 patients with PSC and IBD indicated that anti-TNF agents had moderate clinical efficacy and did not worsen PSC symptoms or lead to specific side-effects, although there are currently no available data regarding hepatobiliary disease [82].”
BackgroundWang, S., Farokhian, A., & Shen, B. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100199 · Cited by 5 · see citing works
“84 85 However, given natural ALP fluctuations and their limited correlation with disease severity, biochemical improvement does not necessarily indicate clinical benefit.”
Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks
Massironi, S., Pirola, L., Mulinacci, G., Ciaccio, A., Viganò, C., Palermo, A., Zilli, A., Invernizzi, P., & Danese, S. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac189 · Cited by 5 · see citing works
Huynh, D., Rubtsov, D., & Khaing, M. M. (2024) · Cureus · doi:10.7759/cureus.56182 · Cited by 5 · see citing works
Treatment of Primary Sclerosing Cholangitis Including Transplantation
Wheless, W. H., & Russo, M. W. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.07.008 · Cited by 4 · see citing works
Díaz‐González, Á., Molera, C., Domínguez, E. G., Muñoz‐Bartolo, G., Ampuero, J., Fernández‐Rodríguez, C., Quintero, J., Molina, E., Salcedo, M., Olveira, A., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502629 · Cited by 3 · see citing works
de Jong, M. J., Zhou, J., Derikx, L. A. A. P., Murad, S. D., van der Meer, A. J., & de Vries, A. C. (2026) · Transplantation · doi:10.1097/tp.0000000000005607 · Cited by 3 · see citing works
Li, D. K., Chaar, A., Arabi, T. Z., Quraishi, M. N., Elgamal, M. H., Alahdab, F., Grimshaw, A. A., & Al‐Bawardy, B. (2026) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izag001 · Cited by 3 · see citing works
Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease
Okada, H., Sugimoto, S., Kayashima, A., Mikami, Y., Kanai∥, T., Nakamoto, N., Collaborators, K. P., Yoshimatsu, Y., Kiyohara, H., Nakadai, Y., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02388-3 · Cited by 3 · see citing works
“Several retrospective studies likewise failed to identify a protective effect of infliximab, adalimumab, or vedolizumab on concomitant PSC [144–146].”
Pediatric Autoimmune Sclerosing Cholangitis: Diagnostic and Therapeutic Challenges
Sucaciu, R.-M., Grama, A., Mititelu, A., Maris, B. R., Filimon, I., Petrushev, B., Popescu, D. C., Bența, G., & Pop, T. L. (2026) · Pediatric Reports · doi:10.3390/pediatric18020054 · Cited by 2 · see citing works
“The transition to adult care services may open some new therapeutic windows, with potential use of other immunosuppressants for the treatment of IBD, which could have positive effects on her liver disease [24].”
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape
Sohal, A., & Kowdley, K. V. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2330738 · Cited by 2 · see citing works
“Although TNF alpha inhibitors have been noted to be safe in patients with IBD and PSC, their use has not been linked to reduction in ALP [105].”
BackgroundThe gut–liver–brain axis: dietary and therapeutic interventions
D’Mello, C., & Swain, M. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821927-0.00007-3 · Cited by 3 · see citing works
Primary sclerosing cholangitis and IgG4-associated cholangitis
Bowlus, C. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00020-5 · Cited by 1 · see citing works
Self-citationLiver Involvement in Celiac Disease and Immune‐Mediated Diseases of the Small Bowel
Nandi, N., Verdu, E. F., Schuppan, D., Gómez-Aldana, A., Pinto-Sánchez, M. I., Conforti, F. S., Maggioni, M., Caprioli, F., & Elli, L. (2025) · Liver International · doi:10.1111/liv.70206 · Cited by 1 · see citing works
“A retrospective study has suggested a potential specific role of Adalimumab in the improvement of cholestasis in PSC [119].”
Abdulla, A. H., Sheikhnoor, A., Ferrao, K., Stiles, L. I., & Mehta, K. J. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02102-w · Cited by 1 · see citing works
Primary Sclerosing Cholangitis
Hussain, N., & Trivedi, P. J. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.013 · Cited by 1 · see citing works
Tosse, R., Maibier, M., Fischer, A., Razpotnik, M., Kouladouros, K., Tacke, F., Sigal, M. J., & Wizenty, J. (2026) · Gastroenterology report · doi:10.1093/gastro/goag079 · Cited by 1 · see citing works
Primary sclerosing cholangitis
Ahmad, J., & Grewal, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26710-9.00019-5 · Cited by 1 · see citing works
Bangma, A., Pibiri, P., Sun, S., de Jong, S., Bigaeva, E., Björk, J. R., Karmi, N., Verstappen, G. M. P. J., Kroese, F. G. M., Kats-Ugurlu, G., et al. (2024) · medRxiv · doi:10.1101/2024.07.23.24310848
Natt, N., May, T. J., Malhi, G., Dumond, J., Gulamhusein, A. F., & Tandon, P. (2025) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwaf023
Immunpathogenese und Therapie der Primär Sklerosierenden Cholangitis
Zecher, B. F., & Schramm, C. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2730-4719
Self-citationEvaluation and management of primary sclerosing cholangitis patients awaiting liver transplantation
Frolkis, A. D., Nayagam, J. S., Parente, A., Seager, M. J., Sadler, M. D., Montaño‐Loza, A. J., & Joshi, D. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101748
“Biologics and small molecules are effective for the treatment of IBD after LT. 156–158 However, biologic therapy in combination with standard post-LT immunosuppression is associated with increased infection risk, 159 particularly with Clostridioides difficile .”
Massironi, S., Fanizzi, F., Invernizzi, F., Furfaro, F., Ciocca, L., Arcari, I., Allocca, M., Peyrin‐Biroulet, L., & Danese, S. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2664055
“Anti-TNFα [118,123].”
Autoimmune liver diseases and overlap syndromes in children with inflammatory bowel diseases
Vazzana, G., Romano, C., Prete, S., & Romano, A. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-06978-4
Elzubeir, A., Kumar, A., McArdle, A., Holden, E., Alexandre, L., Rushbrook, S., & Lynch, K. D. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.71045
Self-citation
- Authors
- Hedin, C. R. H., Sado, G., Ndegwa, N., Lytvyak, E., Mason, A., Montano-Loza, A., Gerussi, A., Saffioti, F., Thorburn, D., Nilsson, E., Larsson, G., Moum, B. A., van Munster, K. N., Ponsioen, C. Y., Levy, C., Nogueira, N. F., Bowlus, C. L., Gotlieb, N., Shibolet, O., Lynch, K. D., Chapman, R. W., Rupp, C., Vesterhus, M., Jørgensen, K. K., Rorsman, F., Schramm, C., Sabino, J., Vermeire, S., Zago, A., Cazzagon, N., Marschall, H.-U., Ytting, H., Ben Belkacem, K., Chazouilleres, O., Almer, S., & Bergquist, A.
- Affiliations
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- University of Alberta (CA)
- National Health Service (GB)
- University of Messina (IT)
- Lund University (SE)
- Oslo University Hospital (NO)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Miami (US)
- University of California Davis Medical Center (US)
- Tel Aviv University (IL)
- University of Oxford (GB)
- University Hospital Heidelberg (DE)
- Haraldsplass Diakonale Sykehus (NO)
- Akershus University Hospital (NO)
- Uppsala University Hospital (SE)
- University Medical Center Hamburg-Eppendorf (DE)
- Universitair Ziekenhuis Leuven (BE)
- University of Padua (IT)
- Sahlgrenska University Hospital (SE)
- Hvidovre Hospital (DK)
- Corresponding author
- Hedin, Charlotte Rose Hawkey
- ORCID
- Hedin, Charlotte Rose Hawkey
- Sado, Gina
- Ndegwa, Nelson
- Lytvyak, Ellina
- Mason, Andrew
- Gerussi, Alessio
- Saffioti, Francesca
- Thorburn, Douglas
- Nilsson, Emma
- Moum, Bjørn A.
- Ponsioen, Cyriel Y.
- Levy, Cynthia
- Nogueira, Nicholas F.
- Bowlus, Christopher L.
- Gotlieb, Neta
- Shibolet, Oren
- Lynch, Kate D.
- Chapman, Roger W.
- Rupp, Christian
- Vesterhus, Mette
- Jørgensen, Kristin K.
- Rorsman, Fredrik
- Schramm, Christoph
- Sabino, João
- Zago, Alessandra
- Cazzagon, Nora
- Marschall, Hanns-Ulrich
- Ytting, Henriette
- Almer, Sven
- Bergquist, Annika
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 18
- Issue
- 10
- Pages
- 2295-2304.e2
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W3006314725
- Cited by
- 52
- References
- 22
- Citations by year
- 2026: 13 · 2025: 10 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 3 · 2020: 2
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Lirias (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Funders
- Università degli Studi di Udine
- Erasmus+
- Cancerfonden
- Stockholms Läns Landsting
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- primary sclerosing cholangitis, inflammatory bowel disease, tumor necrosis factor inhibitors, infliximab, adalimumab, alkaline phosphatase, liver function, endoscopic healing, remission, treatment response, adverse drug reactions
- MeSH terms
- Adalimumab, Infliximab, Tumor Necrosis Factor Inhibitors, Humans, Retrospective Studies, Tumor Necrosis Factor-alpha, Cholangitis, Sclerosing, Inflammatory Bowel Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
